Tezepelumab FDA Approval Expands Use to Nasal Polyps
-
By
October 20, 2025
-
2 min
-
1
Tezepelumab approved for chronic rhinosinusitis with nasal polyps for ages 12+.
-
2
Phase III WAYPOINT trial showed significant symptom improvement.
-
3
Reduces nasal polyp size and congestion.
-
4
Decreased need for systemic corticosteroids and sinus surgery.
-
5
Targets thymic stromal lymphopoietin to block inflammation.
-
6
Available as auto-injector or prefilled syringe.
-
7
Under review in various international markets.
-
8
Already approved for severe asthma globally.
-
Tezepelumab (Tezspire) has been approved by the FDA as an add-on maintenance treatment for patients aged 12 and older suffering from inadequately controlled chronic rhinosinusitis with nasal polyps. Based on phase III WAYPOINT trial data, it showed significant improvements in nasal polyp size, congestion, and reduced need for corticosteroids and surgery. The biologic works by blocking thymic stromal lymphopoietin, targeting the inflammatory process. It is already approved for severe asthma in multiple countries and is available in self-administration forms.
-
1
Tezepelumab approved for chronic rhinosinusitis with nasal polyps for ages 12+.
-
2
Phase III WAYPOINT trial showed significant symptom improvement.
-
3
Reduces nasal polyp size and congestion.
-
4
Decreased need for systemic corticosteroids and sinus surgery.
-
5
Targets thymic stromal lymphopoietin to block inflammation.
-
6
Available as auto-injector or prefilled syringe.
-
7
Under review in various international markets.
-
8
Already approved for severe asthma globally.
Listen Tab content
